Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ciofu, O.
Right arrow Articles by Høiby, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ciofu, O.
Right arrow Articles by Høiby, N.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of Antimicrobial Chemotherapy (1995) 35, 295-304
© 1995 The British Society for Antimicrobial Chemotherapy

research-article

Antibodies against Pseudomonas aeruginosa chromosomal ß-lactamase in patients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to ß-lactams

Oana Ciofua, Birgit Giwercmana,b, Jan Walter-Rasmussenb, Tacjana Presslera,c, Svend Stenvang Pedersenb and Niels Høibya,b

aInstitute of Medical Microbiology and Immunology, University of Copenhagen bDepartment of Clinical Microbiology cDanish Cystic Fibrosis Centre Rigshospitalet, Copenhagen, Denmark

Received 11 May 1994; returned 21 July 1994; accepted 13 September 1994

Chromosomal ß-lactamase production is considered to be the most important resistance mechanism of Pseudomonas aeruginosa against ß-lactams.

Recently we have detected serum and sputum antibodies against P. aeruginosa chromosomal ß-lactamase (aßab), using immunoblotting techniques. In this study we have developed an enzyme-linked-immunosorbent assay to measure serum aßab response in 124 cystic fibrosis patients in a cross-sectional study and in 54 cystic fibrosis patients in a longitudinal study.

The aßab response occurred after a median of 3 years following onset of chronic infection and was significantly higher (P<0·0002) in patients chronically infected with resistant strains than in those from whom resistant strains were occasionally isolated. The aßab levels correlated (r = 0.51, P= 0·0001) with the number of ß-lactam courses. A 14 fold increase in aßab levels occurred during the 14 year period covered by the longitudinal study.

The results of this study show that aßab to P. aeruginosa is a specific marker for resistance development of P. aeruginosa to ß-lactams.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
O. Ciofu, T. J. Beveridge, J. Kadurugamuwa, J. Walther-Rasmussen, and N. Hoiby
Chromosomal {beta}-lactamase is packaged into membrane vesicles and secreted from Pseudomonas aeruginosa
J. Antimicrob. Chemother., January 1, 2000; 45(1): 9 - 13.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
O. Ciofu, T. D Petersen, P. Jensen, and N. Høiby
Avidity of anti-P aeruginosa antibodies during chronic infection in patients with cystic fibrosis
Thorax, February 1, 1999; 54(2): 141 - 144.
[Abstract] [Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.